INSM vs MRNA vs VRTX Stock Comparison

Insmed, Moderna and Vertex Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$27.13B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
2 wins
MRNA Moderna, Inc.
$223.37 -1.3% 1M +794.9% 1Y
Market cap
$86.67B
P/E
–
Revenue (TTM)
$2.53B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

9 decided of 12

Vertex Pharmaceuticals leads on 5 of the 12 questions below (Vertex Pharmaceuticals 5, Insmed 2, Moderna 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionINSMMRNAVRTXLeader
Larger companyMarket capitalisation $27.13B $86.67B $137.64B VRTX
Cheaper on earningsLower P/E, profitable companies only -44.8x -31.1x 34.6x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — 30.4x –
Faster revenue growthRevenue growth, trailing twelve months +240.0% +13.1% +10.5% INSM
More profitableNet margin, trailing twelve months -39.9% -110.5% 30.7% VRTX
Better return on capitalReturn on invested capital -41.1% -39.6% — MRNA
Less leveragedLower net debt / EBITDA 1.1x 1.7x -0.4x VRTX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -36.6% +794.9% +24.0% MRNA
Better 5-year returnAnnualised price return, 5 years +30.6%/yr -0.7%/yr +23.5%/yr INSM
Less volatileAnnualised volatility, 1 year 62.2% 130.6% 29.5% VRTX
Higher overall scoreMean of the five percentile scores vs peers 66/100 60/100 73/100 VRTX

Percentile Scorecard

INSMMRNAVRTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisINSMMRNAVRTX
Valuation 70 #201 of 660 69 #208 of 660 77 #152 of 660
Growth 85 #91 of 619 45 #344 of 619 46 #333 of 619
Profitability 69 #186 of 595 60 #239 of 595 93 #40 of 595
Financial Health 37 #428 of 683 52 #330 of 683 55 #311 of 683
Shareholder Returns 67 #153 of 459 76 #112 of 459 92 #37 of 459
Overall 66 60 73
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MRNA ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VRTX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodINSMMRNAVRTXSPY
1 month +23.9%-1.3%+8.0% -2.0%
3 months -2.1%+252.8%+6.5% -2.8%
6 months +11.0%+355.5%+23.3% +2.0%
Year to date -30.4%+657.4%+18.8% +10.6%
1 year -36.6%+794.9%+24.0% +12.2%
3 years +393.7%+201.4%+45.6% +68.1%
3 years, per year +70.3%+44.5%+13.3% +18.9%
5 years +280.3%-3.4%+187.6% +61.4%
5 years, per year +30.6%-0.7%+23.5% +10.1%
10 years +738.5%—+485.4% +248.5%
10 years, per year +23.7%—+19.3% +13.3%

Risk

MeasureINSMMRNAVRTXSPY
Volatility, 1Y 62.2%130.6%29.5% 13.6%
Downside volatility, 1Y 61.0%79.2%26.1% 13.9%
Beta vs S&P 500, 1Y 0.552.260.43 1.00
Return / volatility, 1Y -0.596.090.81 0.90
Max drawdown, 5Y -56.5%-93.9%-29.1% -25.4%
From 52-week high -42.7%-16.9%-3.6% -3.2%
52-week high $211.41$268.86$558.71 $779.14
52-week low $91.88$22.36$421.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleINSMMRNAVRTX
P/E now vs peer median -43.8xmedian 17.0x -32.1xmedian 17.0x 34.3xmedian 17.0x
P/S now vs peer median 17.5xmedian 8.4x 35.7xmedian 8.4x 10.5xmedian 8.4x
EV/EBITDA now vs peer median -48.6xmedian 14.6x -32.0xmedian 14.6x 29.7xmedian 14.6x
P/FCF now vs peer median -42.3xmedian 19.0x -45.8xmedian 19.0x 42.6xmedian 19.0x
P/B now vs peer median 36.6xmedian 2.0x 13.2xmedian 2.0x 6.5xmedian 2.0x
PEG now vs peer median -2.40median 0.43 -3.01median 0.43 6.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsINSMMRNAVRTX
Revenue $1.52B $2.53B $12.95B
Gross profit $1.28B $707.00M $11.08B
Operating income -$563.99M -$2.93B $4.30B
Net income -$605.67M -$2.79B $3.98B
Free cash flow -$627.58M -$1.97B $3.20B
R&D $944.39M $2.66B $4.25B
EPS (diluted) $-2.77 $-6.49 $15.58
Cash & equivalents $396.60M $1.20B $4.98B
Total debt $555.09M $591.00M $4.50B
Shares (diluted) 218.79M 430.00M 255.20M
Enterprise value $22.17B $65.35B $105.37B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricINSMMRNAVRTX
P/E -43.8x -32.1x 34.3x
P/FCF -42.3x -45.8x 42.6x
P/Operating cash flow -44.6x -50.6x 37.0x
P/S 17.5x 35.7x 10.5x
P/B 36.6x 13.2x 6.5x
P/Tangible book 45.2x 13.2x 11.0x
EV/EBITDA -48.6x -32.0x 29.7x
EV/EBIT -46.1x -29.2x 31.3x
EV/Revenue 17.1x 33.9x 10.4x
EV/FCF -41.4x -43.5x 42.1x
EV/Operating cash flow -43.6x -48.0x 36.5x
PEG (3Y EPS CAGR) -2.40 -3.01 6.39

Growth

14 metrics
MetricINSMMRNAVRTX
Revenue growth (1Y) 240.0% 13.1% 10.5%
Revenue CAGR (3Y) 75.6% -34.8% 10.3%
Gross profit growth (1Y) 274.9% -34.4% 9.5%
Gross profit CAGR (3Y) 79.8% -41.0% 9.3%
Operating income growth (1Y) 51.3% 15.4% 7.8%
Operating income CAGR (3Y) 6.2% -3.2% 3.5%
Net income growth (1Y) 48.8% 10.5% 8.2%
Net income CAGR (3Y) 5.8% 7.0% 4.6%
EPS growth (1Y) 50.5% 18.8% 9.2%
EPS CAGR (3Y) 18.2% 10.7% 5.4%
Operating cash flow growth (1Y) 32.6% 9.8% -0.6%
Operating cash flow CAGR (3Y) -5.4% 4.9% -5.5%
Free cash flow growth (1Y) 30.7% 25.7% -4.0%
Free cash flow CAGR (3Y) -6.2% 9.5% -8.7%

Profitability

14 metrics
MetricINSMMRNAVRTX
Gross margin 84.4% 28.0% 85.5%
EBITDA margin -35.1% -105.9% 35.1%
Operating margin -37.1% -116.0% 33.2%
Pretax margin -39.4% -108.1% 36.7%
Net margin -39.9% -110.5% 30.7%
FCF margin -41.3% -78.0% 24.7%
Operating cash flow margin -39.2% -70.7% 28.5%
Return on equity -81.9% -41.0% 19.3%
Return on assets -28.1% -22.8% 13.2%
Return on invested capital -41.1% -39.6% –
Return on capital employed -36.0% -28.8% 17.2%
Asset turnover 0.7x 0.2x 0.4x
Cash conversion (OCF / net income) 1.0x 0.6x 0.9x
Stock comp / revenue 11.0% 18.4% 5.2%

Financial Health

11 metrics
MetricINSMMRNAVRTX
Debt / assets 24.9% 4.4% 13.7%
Debt / equity 0.8x 0.1x 0.2x
Net debt / EBITDA 1.1x 1.7x -0.4x
Debt / FCF -0.9x -0.3x 1.4x
Liabilities / assets 67.4% 49.2% 36.1%
Equity / assets 32.6% 50.8% 63.9%
Interest coverage -5.5x – 93.0x
Current ratio 2.9x 3.6x 2.3x
Quick ratio 2.4x 3.2x 1.7x
Cash ratio 1.9x 2.5x 1.3x
Altman Z-score 7.36 8.66 8.70

Shareholder Returns

7 metrics
MetricINSMMRNAVRTX
Dividend yield – – –
Net buyback yield -0.4% -0.2% 0.7%
Shareholder yield -0.4% -0.2% 0.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusINSMMRNAVRTX
Forward P/E – – 30.4xFY2026
EPS, next fiscal year $-1.68FY2026 $-7.17FY2026 $17.71FY2026
EPS growth, next FY – – -3.7%FY2026
EPS growth, the year after – – +20.2%
Revenue, next fiscal year $1.99BFY2026 $2.22BFY2026 $12.68BFY2026
Revenue growth, next FY +227.7%FY2026 +14.6%FY2026 +5.9%FY2026
Revenue growth, the year after +59.5% +25.8% +19.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersINSMMRNAVRTX
Held by institutions 100.0% 80.2% 95.1%
Institutions holding 671 787 1,747
Change in shares held, QoQ +3.4% +3.4% +3.9%
Institutions buying 369 404 904
Institutions selling 230 239 605
Buyers to sellers 1.60 1.69 1.49

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

INSMMRNAVRTX
INSM 1.00 0.10 0.25
MRNA 0.10 1.00 0.34
VRTX 0.25 0.34 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, INSM, MRNA and VRTX?

Vertex Pharmaceuticals (VRTX) is the largest by market capitalisation: Insmed (INSM) $27.13B, Moderna (MRNA) $86.67B, Vertex Pharmaceuticals (VRTX) $137.64B.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Insmed (INSM) +240.0%, Moderna (MRNA) +13.1%, Vertex Pharmaceuticals (VRTX) +10.5%.

Which company is more profitable?

Vertex Pharmaceuticals (VRTX) has the highest net margin (Insmed (INSM) -39.9%, Moderna (MRNA) -110.5%, Vertex Pharmaceuticals (VRTX) 30.7%). On return on invested capital, Moderna (MRNA) leads (Insmed (INSM) -41.1%, Moderna (MRNA) -39.6%).

Which stock has performed better?

Over the past year Moderna (MRNA) returned the most: Insmed (INSM) -36.6%, Moderna (MRNA) +794.9%, Vertex Pharmaceuticals (VRTX) +24.0%. Over five years, Insmed (INSM) compounded fastest (Insmed (INSM) +30.6%/yr, Moderna (MRNA) -0.7%/yr, Vertex Pharmaceuticals (VRTX) +23.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Vertex Pharmaceuticals (VRTX) has been the steadiest (Insmed (INSM) 62.2%, Moderna (MRNA) 130.6%, Vertex Pharmaceuticals (VRTX) 29.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, INSM, MRNA and VRTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Vertex Pharmaceuticals (VRTX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.